In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TriVascular Technologies Inc.

Division of Endologix Inc.
www.trivascular.com

Latest From TriVascular Technologies Inc.

Device/Diagnostics Quarterly Deal-Making Statistics, Q2 2017

Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.

Medical Device In Vitro Diagnostics

Endologix Joins Gender-Specific Movement To Target Women

One-month results from the LUCY trial show that Endologix Ovation abdominal aortic aneurysm (AAA) stent graft, designed specifically for female anatomy, could make 28% more women eligible for a AAA endograft. LUCY, the first study to specifically evaluate endovascular aneurysm repair in women, is part of a trend of research focused on women's outcomes with cardiovascular devices.

Cardiovascular Clinical Trials

EVAR Update: Companies Target Complex Anatomies With Innovative Solutions

As endovascular aortic repair (EVAR) becomes a mainstream procedure, companies are racing to develop products that can treat patients with more challenging anatomy. As the space bubbles with ongoing trials and new-product launches, newer companies hope to make their mark in a space dominated by the established market leaders Medtronic PLC, Cook Medical Inc. and WL Gore & Associates.

Medical Device Innovation

Device/Diagnostics Quarterly Deal Statistics, Q4 2015

At $1.2 billion, Q4 device financing was the second-lowest quarter of 2015; M&A dollar volume was also low, but included multiple deals across various cardiovascular markets. Diagnostics financing was also down in Q4, totaling $403 million; acquisitions were worth $441 million.

Medical Device Deals
See All

Company Information

  • Industry
  • Medical Devices
    • Biomaterials
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
      • Surgical Sealants
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • TriVascular2 Inc.
  • TriVascular Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Endologix Inc.
  • Senior Management
  • Christopher G Chavez, PhD, Chmn., Pres. & CEO
    Michael R Kramer, CFO
    Michael V Chobotov, PhD, CTO
    Vivek K Jayaraman, VP, Global Sales & Mktg.
  • Contact Info
  • TriVascular Technologies Inc.
    Phone: (707) 543-8800
    3910 Brickway Blvd.
    Santa Rosa , CA 95403
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register